Tango for Alzheimer's Disease Patients' Caregivers
NCT03269149, Not applicable, Completed, Emory University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Tango for Alzheimer's Disease Patients' Caregivers | ClinicalTrials.gov |
| NCT number | NCT03269149 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 50 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Emory University | ClinicalTrials.gov |
| Conditions | Alzheimer's Disease | ClinicalTrials.gov |
| Interventions | Adapted Tango Dance, Educational lectures | ClinicalTrials.gov |
| First posted | 2017-08-31 | ClinicalTrials.gov |
| Last updated | 2026-05-26 | ClinicalTrials.gov |
Registered outcomes 28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in interleukin-7 | Before and after the intervention / control at least 20 times during 12 weeks | 45 mL blood will be acquired before and after the intervention to measure the inflammatory and stress marker levels | ClinicalTrials.gov |
| Primary | Change in interleukin-8 | Before and after the intervention / control at least 20 times during 12 weeks | 45 mL blood will be acquired before and after the intervention to measure the inflammatory and stress marker levels | ClinicalTrials.gov |
| Primary | Change in interleukin-9 | Before and after the intervention / control at least 20 times during 12 weeks | 45 mL blood will be acquired before and after the intervention to measure the inflammatory and stress marker levels | ClinicalTrials.gov |
| Primary | Change in Interleukin-10 | Before and after the intervention / control at least 20 times during 12 weeks | 45 mL blood will be acquired before and after the intervention to measure the inflammatory and stress marker levels | ClinicalTrials.gov |
| Primary | Change in interferon induced protein 10 | Before and after the intervention / control at least 20 times during 12 weeks | 45 mL blood will be acquired before and after the intervention to measure the inflammatory and stress marker levels | ClinicalTrials.gov |
| Primary | Change in macrophage derived chemokine | Before and after the intervention / control at least 20 times during 12 weeks | 45 mL blood will be acquired before and after the intervention to measure the inflammatory and stress marker levels | ClinicalTrials.gov |
| Primary | Change in monocyte chemoattractant protein 1 | Before and after the intervention / control at least 20 times during 12 weeks | 45 mL blood will be acquired before and after the intervention to measure the inflammatory and stress marker levels | ClinicalTrials.gov |
| Primary | Change in transforming growth factor alpha | Before and after the intervention / control at least 20 times during 12 weeks | 45 mL blood will be acquired before and after the intervention to measure the inflammatory and stress marker levels | ClinicalTrials.gov |
| Primary | Change in tumor necrosis factor alpha | Before and after the intervention / control at least 20 times during 12 weeks | 45 mL blood will be acquired before and after the intervention to measure the inflammatory and stress marker levels | ClinicalTrials.gov |
| Primary | Change in C-reactive protein | Before and after the intervention / control at least 20 times during 12 weeks | 45 mL blood will be acquired before and after the intervention to measure the inflammatory and stress marker levels | ClinicalTrials.gov |
| Primary | Change in serum amyloid protein | Before and after the intervention / control at least 20 times during 12 weeks | 45 mL blood will be acquired before and after the intervention to measure the inflammatory and stress marker levels | ClinicalTrials.gov |
| Secondary | Change in Montreal Cognitive Assessment (MoCA) | Before and after the intervention / control, offered twice per week, at least 20 times during 12 weeks | The MoCA test is a 30-point test that assesses several cognitive domains. The short-term memory recall task (5 points) ; Visuospatial abilities are assessed using a clock-drawing task (3 points) and a three-dimensional cube copy (1 point); executive functions are assessed using an alternation task adapted from the trail-making B task (1 point), a phonemic fluency task (1 point), and a two-item verbal abstraction task (2 points). Attention, concentration and working memory are evaluated using a attention task (target detection using tapping; 1 point), a serial subtraction task (3 points), and digits forward and backward (1 point each). Language is assessed using a confrontation naming task with low-familiarity animals (3 points), repetition of two syntactically complex sentences (2 points), and the aforementioned fluency task. Finally, orientation to time and place is evaluated (6 points). | ClinicalTrials.gov |
| Secondary | Change in the Tower of London test | Before and after the intervention / control, offered twice per week, at least 20 times during 12 weeks | The Tower of London test is used for the assessment of executive functioning specifically to detect deficits in planning. It is related to the classic problem-solving puzzle known as the Tower of Hanoi.The test consists of two boards with pegs and several beads with different colors. The examiner uses the beads and the boards to present the examinee with problem-solving tasks. The performance of the examinee is compared to representative samples of individuals of the same age to derive hypotheses about the person's executive cognitive ability. | ClinicalTrials.gov |
| Secondary | Change in the Stroop interference test | Before and after the intervention / control, offered twice per week, at least 20 times during 12 weeks | The Stroop test is to name the color in which a word is printed, ignoring the word itself. The Stroop Test is used to assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the imultaneous processing of a second stimulus attribute, well-known as the Stroop Effect. Total time needed for each card is the outcome variable. | ClinicalTrials.gov |
| Secondary | Change in Trails B test | Before and after the intervention / control, offered twice per week, at least 20 times during 12 weeks | Trail Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. The time taken to complete the test is used as the primary performance metric.The test is sensitive to detecting cognitive impairment. | ClinicalTrials.gov |
| Secondary | Change in Digit Span test | Before and after the intervention / control, offered twice per week, at least 20 times during 12 weeks | The Digit Span test is either conducted verbally or using a computer program. A sequence of numbers is shown or read out to the participant. The participant is then told to repeat the numbers that were shown or read to them. This process continues until the participant can no longer remember either the full sequence of numbers or the correct order.The Digit Span test is scored by the amount of numbers the participant was able to remember in each test. The scorer must add the total number of correct sequences, backwards and forwards. | ClinicalTrials.gov |
| Secondary | Change in Buschke Selective Reminding Test | Before and after the intervention / control, offered twice per week, at least 20 times during 12 weeks | The Buschke Selective Reminding Test (SRT) is a test designed to measure verbal learning and memory through the use of a list-learning procedure over multiple trials. The adult SRT involves reading the subject a list of 12 unrelated words and then having the subject immediately recall as many of these 12 words as possible. Every trial after the first involves selectively presenting only those words in which the subject did not recall on the immediately preceding trial. The selective reminding trials proceed in this manner until the subject is able to correctly recall all 12 words on three consecutive trials, or until 12 trials have been completed. Scoring of the test has been automated according the instructions of Buschke. | ClinicalTrials.gov |
| Secondary | Change in Reverse Corsi Blocks test | Before and after the intervention / control, offered twice per week, at least 20 times during 12 weeks | The Corsi block-tapping test is a psychological test that assesses visuo-spatial short term working memory. It involves mimicking a researcher as he/she taps a sequence of up to nine identical spatially separated blocks. The sequence starts out simple, usually using two blocks, but becomes more complex until the subject's performance suffers. This number is known as the Corsi Span, and averages about 5 for normal human subjects. | ClinicalTrials.gov |
| Secondary | Change in Brooks spatial memory test | Before and after the intervention / control, offered twice per week, at least 20 times during 12 weeks | Brooks spatial memory task (BSMT): In the BSMT, the participant visualizes a 4x4 matrix in which the location of numbers 1 through 8 is described. Participants practice with 3 instructions and progress up to 8 instructions. All levels are completed regardless of errors. Percentages correct (out of 50) will be used for analysis. | ClinicalTrials.gov |
| Secondary | Change in the Body position spatial task (BPST) | Before and after the intervention / control, offered twice per week, at least 20 times during 12 weeks | Body position spatial task (BPST) measures whole body knowledge of spatial position and ability to navigate in a remembered path. The examiner verbally and visually demonstrates combinations of 5 possible moves: step forward, step left, step right, quarter turn left, and quarter turn right. The examiner begins with 2 moves and progresses up to 9 moves, with 2 trials per level. Participants continue to the next level if one trial is correctly performed. The test ends when participants miss both trials of a level. Span length and number of correct trials are variables. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 12
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Arithmetic Fluency Task | Secondary outcome | ConductCognition |
| Clock Drawing Task | Secondary outcome | ConductCognition |
| Corsi Block-Tapping Test | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Selective Reminding Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Task Switching Test | Secondary outcome | ConductCognition |
| Tower Planning | Secondary outcome | ConductCognition |
| Tower of Hanoi | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)